Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 138530-94-6
Drug Levels and Effects
Summary of Use during Lactation
Dexlansoprazole is the R-enantiomer of the proton-pump inhibitor, lansoprazole. No information is available on the use of dexlansoprazole or lansoprazole during breastfeeding. However, lansoprazole has been used safely in newborn infants, so it is unlikely that the amount of dexlansoprazole in breastmilk would be harmful.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
A retrospective claims database study in the United States found that users of proton pump inhibitors had an increased risk of gynecomastia.[1]
A review article reported that a search of database from the European Pharmacovigilance Centre found 1 case of gynecomastia, no cases of galactorrhea, 1 cases of breast pain and 1 case of breast enlargement associated with dexlansoprazole. A search of the WHO global pharmacovigilance database found 2 cases of gynecomastia, no cases of galactorrhea, 4 cases of breast pain and 1 case of breast enlargement associated with dexlansoprazole.[2]
Alternate Drugs to Consider
Antacids, Cimetidine, Famotidine, Omeprazole, Pantoprazole, Sucralfate
References
- 1.
- He B, Carleton B, Etminan M. Risk of gynecomastia with users of proton pump inhibitors. Pharmacotherapy. 2019;39:614–8. [PubMed: 30865318]
- 2.
- Ashfaq M, Haroon MZ, Alkahraman YM. Proton pump inhibitors therapy and risk of hyperprolactinemia with associated sexual disorders. Endocr Regul. 2022;56:134–47. [PubMed: 35489049]
Substance Identification
Substance Name
Dexlansoprazole
CAS Registry Number
138530-94-6
Drug Class
Breast Feeding
Milk, Human
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Dexlansoprazole - Drugs and Lactation Database (LactMed®)Dexlansoprazole - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...